Syntara Dirección

Dirección controles de criterios 2/4

El CEO de Syntara es Gary Phillips , nombrado en Mar 2013, tiene una permanencia de 11.67 años. compensación anual total es A$830.67K, compuesta por 56.7% salario y 43.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.42% de las acciones de la empresa, por valor de A$262.20K. La antigüedad media del equipo directivo y de la junta directiva es de 4.7 años y 4.7 años, respectivamente.

Información clave

Gary Phillips

Chief Executive Officer (CEO)

AU$830.7k

Compensación total

Porcentaje del salario del CEO	56.7%
Permanencia del CEO	11.7yrs
Participación del CEO	0.4%
Permanencia media de la dirección	4.7yrs
Promedio de permanencia en la Junta Directiva	4.7yrs

Actualizaciones recientes de la dirección

Recent updates

Improved Revenues Required Before Syntara Limited (ASX:SNT) Stock's 36% Jump Looks Justified

Jul 05

Syntara Limited (ASX:SNT) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough

Apr 29

Syntara Limited's (ASX:SNT) Low P/S No Reason For Excitement

Mar 14

We're Hopeful That Pharmaxis (ASX:PXS) Will Use Its Cash Wisely

Feb 28

Shareholders May Not Be So Generous With Pharmaxis Ltd's (ASX:PXS) CEO Compensation And Here's Why

Oct 27

Key Things To Understand About Pharmaxis' (ASX:PXS) CEO Pay Cheque

Mar 01

We Think Pharmaxis (ASX:PXS) Can Afford To Drive Business Growth

Jan 04

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Gary Phillips en comparación con los beneficios de Syntara?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	AU$831k	AU$471k	-AU$14m
Mar 31 2024	n/a	n/a	-AU$10m
Dec 31 2023	n/a	n/a	-AU$11m
Sep 30 2023	n/a	n/a	-AU$18m
Jun 30 2023	AU$754k	AU$462k	-AU$13m
Mar 31 2023	n/a	n/a	AU$2m
Dec 31 2022	n/a	n/a	-AU$2m
Sep 30 2022	n/a	n/a	AU$2m
Jun 30 2022	AU$628k	AU$451k	-AU$2m
Mar 31 2022	n/a	n/a	-AU$16m
Dec 31 2021	n/a	n/a	-AU$12m
Sep 30 2021	n/a	n/a	-AU$1m
Jun 30 2021	AU$683k	AU$444k	-AU$3m
Mar 31 2021	n/a	n/a	AU$5m
Dec 31 2020	n/a	n/a	-AU$4m
Sep 30 2020	n/a	n/a	-AU$13m
Jun 30 2020	AU$559k	AU$440k	-AU$14m
Mar 31 2020	n/a	n/a	-AU$21m
Dec 31 2019	n/a	n/a	-AU$18m
Sep 30 2019	n/a	n/a	-AU$18m
Jun 30 2019	AU$613k	AU$433k	-AU$20m
Mar 31 2019	n/a	n/a	-AU$27m
Dec 31 2018	n/a	n/a	-AU$12m
Sep 30 2018	n/a	n/a	-AU$22m
Jun 30 2018	AU$776k	AU$424k	AU$6m

Compensación vs. Mercado: La compensación total de Gary($USD540.13K) está por encima de la media de empresas de tamaño similar en el mercado Australian ($USD298.55K).

Compensación vs. Ingresos: La compensación de Gary ha aumentado mientras la empresa no es rentable.

CEO

Gary Phillips (63 yo)

11.7yrs

Permanencia

AU$830,674

Compensación

Mr. Gary Jonathan Phillips, BPharm, MBA, serves as Independent Non-Executive Director at Arovella Therapeutics Limited since July 1, 2022. He has been Chief Executive Officer and Managing Director of Synta...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Gary Phillips	CEO, MD & Director	11.7yrs	AU$830.67k	0.42% A$ 262.2k
Wolfgang Jarolimek	Head of Drug Discovery	12.3yrs	AU$533.03k	0.13% A$ 79.2k
Kristen Morgan	Head of Medical & Regulatory Affairs - Alliance Management	no data	AU$360.60k	0.024% A$ 15.0k
Jana Baskar	Chief Medical Officer	2.3yrs	AU$455.75k	0.11% A$ 70.7k
David McGarvey	Company Secretary	less than a year	AU$603.03k	0.076% A$ 47.8k
Timothy Luscombe	Chief Financial Officer	less than a year	sin datos	sin datos
Cameron Billingsley	General Counsel	no data	sin datos	sin datos
Dieter Hamprecht	Head of Chemistry	7.1yrs	sin datos	sin datos

4.7yrs

Permanencia media

60yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SNT se considera experimentado (4.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Gary Phillips	CEO, MD & Director	11.7yrs	AU$830.67k	0.42% A$ 262.2k
Simon Green	Independent Non-Executive Director	1.9yrs	AU$73.63k	0.066% A$ 41.8k
Kathleen M. Metters	Independent Non Executive Chair	7.4yrs	AU$112.80k	0.0015% A$ 922.2
Waradana Malitha De Silva	Non-Executive Director	1.8yrs	AU$73.63k	0.023% A$ 14.6k

4.7yrs

Permanencia media

Junta con experiencia: La junta directiva de SNT se considera experimentada (4.7 años de antigüedad promedio).

Syntara Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Syntara Limited, Annual General Meeting, Nov 28, 2024

Syntara Limited Announces CFO Changes

Pharmaxis Ltd, Annual General Meeting, Nov 28, 2023

Pharmaxis Ltd Appoints Hashan De Silva to the Board as Nonexecutive Director

Pharmaxis Ltd Announces the Appointment of Simon Green to the Board as an Independent Nonexecutive Director

Less than half of directors are independent

Recent updates

Syntara Limited to Report Q1, 2025 Results on Oct 30, 2024

Syntara Limited, Annual General Meeting, Nov 28, 2024

Syntara Limited Announces CFO Changes

Improved Revenues Required Before Syntara Limited (ASX:SNT) Stock's 36% Jump Looks Justified

New major risk - Financial position

New minor risk - Financial position

New minor risk - Financial position

Syntara Limited (ASX:SNT) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough

Syntara Limited to Report Q3, 2024 Results on Apr 30, 2024

Syntara Limited's (ASX:SNT) Low P/S No Reason For Excitement

Price target decreased by 41% to AU$0.20

New major risk - Shareholder dilution

Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Syntara Limited has filed a Follow-on Equity Offering in the amount of AUD 10.0012 million.

New major risk - Financial position

New minor risk - Financial position

Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis.

Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis.

New major risk - Revenue and earnings growth

Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis.

Pharmaxis Ltd, Annual General Meeting, Nov 28, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2026

New minor risk - Financial data availability

Price target decreased by 32% to AU$0.17

Second quarter 2023 earnings released: AU$0.008 loss per share (vs AU$0.01 loss in 2Q 2022)

Pharmaxis Ltd Appoints Hashan De Silva to the Board as Nonexecutive Director

Pharmaxis Announces Clinical Trial of Its Topical Anti Scarring Drug PXS6302 Complete Recruitment with the Last of the 42 Patients

Pharmaxis Ltd Announces the Appointment of Simon Green to the Board as an Independent Nonexecutive Director

Pharmaxis Ltd to Report Q3, 2023 Results on Apr 28, 2023

Less than half of directors are independent

First quarter 2023 earnings released

Pharmaxis Ltd, Annual General Meeting, Nov 29, 2022

Pharmaxis Ltd Announces Positive Interim Data from Myelofibrosis Trial

Pharmaxis Ltd Releases Promising Interim Data from Skin Scarring Study

Pharmaxis Ltd Updates on Phase 2 Study of the Pharmaxis Drug Discovery PXS4728

Full year 2022 earnings: Revenues exceed analyst expectations

Pharmaxis Ltd to Report Fiscal Year 2022 Final Results on Aug 23, 2022

Pharmaxis Ltd Announces Resignation of Will Delaat as Non Executive Director

Full year 2022 earnings: Revenues miss analyst expectations

Pharmaxis Limited Announces the Appointment of Dr. Jana Baskar as Chief Medical Officer

Pharmaxis Ltd, Annual General Meeting, Jul 11, 2022

Pharmaxis Ltd to Report Fiscal Year 2022 Results on Aug 11, 2022

Price target increased to AU$0.58

Less than half of directors are independent

We're Hopeful That Pharmaxis (ASX:PXS) Will Use Its Cash Wisely

Second quarter 2022 earnings: Revenues exceed analyst expectations

Pharmaxis Ltd Announces First Patients Dosed in PXS Scar Reduction Trial

Independent Chairman of the Board recently bought AU$113k worth of stock

First quarter 2022 earnings released: AU$0.007 loss per share

Shareholders May Not Be So Generous With Pharmaxis Ltd's (ASX:PXS) CEO Compensation And Here's Why

Pharmaxis Ltd Announces Results of Data Analysis from the Second of Three Stages in Its Phase 1C Clinical Trial (MF-101) Studying Potential New Treatment for the Bone Marrow Cancer Myelofibrosis

Pharmaxis Announces Progression of Clinical Trial in Bone Marrow Cancer

Pharmaxis Ltd announced that it expects to receive AUD 4.366891 million in funding from Karst Peak Capital Limited, BVF Partners, L.P.

Key Things To Understand About Pharmaxis' (ASX:PXS) CEO Pay Cheque

Pharmaxis Announces First Patient Enrolled in Clinical Trial for New Cancer Treatment

Analysts lower EPS estimates to -AU$0.014

Pharmaxis Exports CF Drug to US

Second quarter 2021 earnings released

Revenue and earnings miss expectations

We Think Pharmaxis (ASX:PXS) Can Afford To Drive Business Growth

Pharmaxis Receives USD 7 Million Milestone from Chiesi

Pharmaxis Ltd, Annual General Meeting, Nov 03, 2021

Pharmaxis to Present at Proactive CEO Investor Session

First quarter earnings released

Price target lowered to AU$0.09

Pharmaxis Ltd Auditor Raises 'Going Concern' Doubt

Análisis de compensación del CEO

CEO